Skip to main content
SpringerLink
Log in

Host Factor Pharmacogenetics for Treatment of Infectious Diseases

  • Chapter
Molecular Pathology in Clinical Practice

  • 3543 Accesses

Abstract

Progress in therapeutics and testing for infectious diseases over the past 100 years has resulted in dramatic reductions in morbidity and mortality. However, with developments of effective drugs has come the recognition that not all individuals respond the same to a given therapy, and this marked the beginning of initiatives to study human genetic variations as a factor in response to drug therapy. The pharmacogenetics of infectious diseases is in its infancy; however, the goal of maximizing drug efficacy while minimizing toxicity has important implications for clinical care and better understanding of the biology of the host-pathogen interface. This chapter provides an overview of the progress that has been made in pharmacogenetics and summarizes the challenges that remain for bridging the gap between research and clinical use. The few illustrative examples of genetic testing currently utilized as tools for patient management are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Becquemont L. HLA: a pharmacogenomics success story. Pharmacogenomics. 2010;11(3):277–81. doi:10.2217/pgs.10.38.

    Article  PubMed  Google Scholar 

  2. Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009;360(17):1696–8. doi:10.1056/NEJMp0806284.

    Article  CAS  PubMed  Google Scholar 

  3. Hirschhorn JN. Genome-wide association studies–illuminating biologic pathways. N Engl J Med. 2009;360(17):1699–701. doi:10.1056/NEJMp0808934.

    Article  CAS  PubMed  Google Scholar 

  4. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–2.

    Article  CAS  PubMed  Google Scholar 

  5. Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read. 2001;11(4):222–6.

    CAS  PubMed  Google Scholar 

  6. Peyriere H, Nicholas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother. 2001;35(10):1291–2.

    Article  Google Scholar 

  7. Hughes AR, Mosteller M, Bansal AT, Davies K, Hameline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all populations. Pharmaocogenomics. 2004;5(2):203–11.

    Article  CAS  Google Scholar 

  8. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32.

    Article  CAS  PubMed  Google Scholar 

  9. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Zea C. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;29(1):165.

    Article  CAS  Google Scholar 

  10. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979–81.

    Article  CAS  PubMed  Google Scholar 

  11. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;10(12):4180–5.

    Article  Google Scholar 

  12. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99–102.

    Article  CAS  PubMed  Google Scholar 

  13. Mallal SA, Phillips E, Carosi G, Molina JM, Workman C, Jea T. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–79.

    Article  PubMed  Google Scholar 

  14. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther. 2003;8(2):36–41.

    CAS  PubMed  Google Scholar 

  15. Saag MS, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111–8.

    Article  CAS  PubMed  Google Scholar 

  16. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025–33. doi:10.1097/QAD.0b013e3283103ce6.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14(6):335–42.

    Article  PubMed  Google Scholar 

  18. Department of Health and Human Services PoAGfAaA (2008) Guidelines for the Use of antiretroviral agents in HIV-1-infected adults and adolescents.

    Google Scholar 

  19. Colombo S, Rauch A, Rotger M. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis. 2008;198(9):1415.

    Article  CAS  Google Scholar 

  20. Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K, Silva-Zolezzi I, Fernandez-Lopez JC, Jimenez-Sanchez G, Carnevale A. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. Pharmacogenomics. 2011;12(6):809–14. doi:10.2217/pgs.11.31.

    Article  CAS  PubMed  Google Scholar 

  21. Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens. 2005;65(6):571–4. doi:10.1111/j.1399-0039.2005.00401.x.

    Article  CAS  PubMed  Google Scholar 

  22. Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens. 2007;70(1):58–61. doi:10.1111/j.1399-0039.2007.00840.x.

    Article  CAS  PubMed  Google Scholar 

  23. Badulli C, Sestini R, Sbarsi I, Baroncelli M, Pizzochero C, Martinetti M, Porfirio B. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population. Pharmacogenomics. 2012;13(3):247–9. doi:10.2217/pgs.11.168.

    Article  CAS  PubMed  Google Scholar 

  24. Phillips E, Nolan D, Thornborn D, Schaefer M, Laird R, Rauch A, et al. Genetic factors predicting abacavir hypersensitivity and tolerance in HLA-B*5701 positive individuals. Eur J Dermatol. 2008;18(2):247.

    Google Scholar 

  25. Morgan T, Ghany M, Kim H, Snow K, Shiffman ML, De Santo J, Lee W, Di Bisceglie A, Bonkovsky H, Dienstag J, Morishima C, Lindsay K, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44. doi:10.1002/hep.24641.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9. doi:10.1038/ng.449. ng.449 [pii].

    Article  CAS  PubMed  Google Scholar 

  28. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. doi:10.1038/nature08463.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi:10.1038/nature08309.

    Article  CAS  PubMed  Google Scholar 

  30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4. doi:10.1038/ng.447. ng.447 [pii].

    Article  CAS  PubMed  Google Scholar 

  31. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis CCS, Swiss HIVCS. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45. doi:10.1053/j.gastro.2009.12.056. 1345.e1331-1337.

    Article  CAS  PubMed  Google Scholar 

  32. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–129.e118. doi:10.1053/j.gastro.2010.04.013.

    Article  CAS  PubMed  Google Scholar 

  33. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821–7. doi:10.1053/j.gastro.2010.05.079. 827.e821.

    Article  CAS  PubMed  Google Scholar 

  34. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79(6):3851–4. doi:10.1128/JVI.79.6.3851-3854.2005.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology. 2010;138(4):1240–3. doi:10.1053/j.gastro.2010.02.033.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421–9. doi:10.1002/hep.23690.

    Article  CAS  PubMed  Google Scholar 

  37. Poordad F, Bronowicki JP, Gordon S, Zeuzem S, Jacobson IM, Sulkowski M, et al. IL28B polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol. 2011;54 suppl 1:S6.

    Article  Google Scholar 

  38. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improves SVR rates across all IL28b genotypes in the advanced trial. J Hepatol. 2011;54(S1):S1369.

    Google Scholar 

  39. Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, Slev PR. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn. 2011;13(4):446–51. doi:10.1016/j.jmoldx.2011.03.008.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res. 2010;40(5):449–60. HEP671 [pii].

    Article  CAS  PubMed  Google Scholar 

  41. Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet. 2011;20(17):3507–16. doi:10.1093/hmg/ddr249.

    Article  CAS  PubMed  Google Scholar 

  42. Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010;40(11):1063–71. doi:10.1111/j.1872-034X.2010.00741.x.

    Article  CAS  PubMed  Google Scholar 

  43. Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011;83(6):1048–57. doi:10.1002/jmv.22069.

    Article  CAS  PubMed  Google Scholar 

  44. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405–8. doi:10.1038/nature08825.

    Article  CAS  PubMed  Google Scholar 

  45. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011;53:389. doi:10.1002/hep.24068.

    Article  CAS  PubMed  Google Scholar 

  46. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 2010;85(1):190–200. doi:10.1016/j.antiviral.2009.09.001.

    Article  CAS  PubMed  Google Scholar 

  47. Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis. 2008;21(1):16–24. doi:10.1097/QCO.0b013e3282f42224.

    Article  CAS  PubMed  Google Scholar 

  48. Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, Dube MP, Tebas P, Reilly MP. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3(3):e52. doi:10.1371/journal.pmed.0030052.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE, Swiss HIVCS. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics. 2007;17(9):755–64. doi:10.1097/FPC.0b013e32814db8b7.

    Article  CAS  PubMed  Google Scholar 

  50. Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124(3220):484–5.

    CAS  PubMed  Google Scholar 

  51. Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull World Health Organ. 2011;89(11):838–45.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med. 1990;83(2):82–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  53. GlaxoSmithKline. Update on GSK’s malaria treatments: Dacart and Lapdap, 2008.

    Google Scholar 

  54. Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol. 2011;7(10):1185–200. doi:10.1517/17425255.2011.608660.

    Article  CAS  PubMed  Google Scholar 

  55. Raymond JM, Dumas F, Baldit C, Couzigou P, Beraud C, Amouretti M. Fatal acute hepatitis due to amodiaquine. J Clin Gastroenterol. 1989;11(5):602–3.

    Article  CAS  PubMed  Google Scholar 

  56. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet. 1996;348(9036):1196–201. doi:10.1016/S0140-6736(96)06217-4.

    Article  CAS  PubMed  Google Scholar 

  57. Ferreira PE, Cavaco I, Gil JP. Pharmacogenetic tools for malaria and TB in the Developing World. Fut Med. 2008;5(6):627–39.

    CAS  Google Scholar 

  58. Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005;61(1):15–8. doi:10.1007/s00228-004-0871-8.

    Article  CAS  PubMed  Google Scholar 

  59. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, le Thu TA, Hung NC, Pirmohamed M, Park BK, Edwards G. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002;30(9):1005–12.

    Article  CAS  PubMed  Google Scholar 

  60. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab. 2009;10(7):754–80.

    Article  CAS  PubMed  Google Scholar 

  61. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320(5874):330–4. doi:10.1126/science.1155165.

    Article  CAS  PubMed  Google Scholar 

  62. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med. 2009;361(5):540–1. doi:10.1056/NEJMc0900231.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, School of Medicine, University of Utah, Salt Lake City, UT, USA

    Patricia R. Slev Ph.D., D.(A.B.C.C.) & David R. Hillyard M.D.

  2. Serologic Hepatitis & Retrovirus Laboratory, ARUP Laboratories, MS 115 - Medical Directors, 500 Chipeta Way, Salt Lake City, UT, 84108, USA

    Patricia R. Slev Ph.D., D.(A.B.C.C.)

  3. Immunology Core Laboratory, ARUP Laboratories, MS 115 - Medical Directors, 500 Chipeta Way, Salt Lake City, UT, 84108, USA

    Patricia R. Slev Ph.D., D.(A.B.C.C.)

  4. Molecular Infectious Disease Testing and Infectious Disease Sequencing Core, ARUP Laboratories, Salt Lake City, UT, USA

    David R. Hillyard M.D.

Authors
  1. Patricia R. Slev Ph.D., D.(A.B.C.C.)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David R. Hillyard M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia R. Slev Ph.D., D.(A.B.C.C.) .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, University of Vermont College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA

    Debra G.B. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Slev, P.R., Hillyard, D.R. (2016). Host Factor Pharmacogenetics for Treatment of Infectious Diseases. In: Leonard, D. (eds) Molecular Pathology in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-19674-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19674-9_20

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19673-2

  • Online ISBN: 978-3-319-19674-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation